secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2022-05-24T23:59:59+00:00
Accession:  0001104659-22-064024
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves United Therapeutics' Tyvaso DPI for PAH and PH-ILD; launch underway
--------------------------------------------------------------------------------

- FDA approved Tyvaso DPI (treprostinil inhalation powder) for PAH (WHO Group 1) and PH-ILD (WHO Group 3).
- First dry powder inhaler approved for PAH and PH-ILD; patient availability expected June 2022.
- BREEZE study (51 PAH patients) demonstrated safety/tolerance and improved 6-minute walk distance.
- TYVASO DPI and Tyvaso Inhalation Solution are only FDA-approved therapies for PH-ILD.
- Commercial launch activities underway, offering convenient treprostinil delivery via hand-held inhaler.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000110465922064024/0001104659-22-064024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000110465922064024/tm2216671d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-064024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer